We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Beta-Blockers Enhance the Pro-Survival Function of Mef2 in Post-Heart Attack Cardiomyocytes

By LabMedica International staff writers
Posted on 28 Sep 2015
Cardiac disease researchers have found that beta-blockers such as Atenolol act to prevent cell death following a heart attack by enhancing the activity of myocyte enhancer factor 2 (Mef2) proteins, which function as important regulators of myocardial gene expression.

In adult tissues, Mef2 proteins regulate the stress-response during cardiac hypertrophy and tissue remodeling in cardiac and skeletal muscle. More...
Investigators at York University (Toronto, Canada) had shown previously that MEF2 gene activity was suppressed by beta1-adrenergic receptor (beta1-AR) stimulation, which after heart attack, increased apoptosis in cardiomyocytes through activation of cAMP/protein kinase A (PKA) signaling.

The adrenergic receptors (subtypes alpha 1, alpha 2, beta 1, and beta 2) are a prototypic family of guanine nucleotide binding regulatory protein-coupled receptors that mediate the physiological effects of the hormone epinephrine and the neurotransmitter norepinephrine. Specific polymorphisms in this gene have been shown to affect the resting heart rate and can be involved in heart failure. In addition, flow cytometry identified siRNA-mediated gene silencing of MEF2 as inducing cardiomyocyte apoptosis.

In a follow-up study published in the September 14, 2015, online edition of the journal Cell Death Discovery, the investigators reported that beta1-AR-mediated apoptosis was abrogated in cardiomyocytes expressing a PKA-resistant form of MEF2. They also showed that a beta1-blocker, Atenolol, antagonized the apoptosis pathway while concomitantly enhancing MEF2 transcriptional activity. Beta-AR stimulation modulated MEF2 cellular localization in cardiomyocytes, and this effect was reversed by beta-blocker treatment. Furthermore, Kruppel-like factor 6 (KFL6), a MEF2 target gene in the heart, functioned as a downstream pro-survival factor in cardiomyocytes.

Collectively, these data indicated that (a) MEF2 had an important pro-survival role in cardiomyocytes, and (b) beta-adrenergic signaling antagonized the pro-survival function of MEF2 in cardiomyocytes and beta-blockers promoted it.

Senior author Dr. John McDermott, professor of biology at York University, said, "An initial clue was the accumulating evidence that the primary function of the MEF2 protein complex in neurons is to protect them from dying off. We suspected that these proteins might play a similar role in the heart."

Related Links:

York University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.